SCHEMBL14358232

SCHEMBL14358232

Brc1ccc2c(n1)OCCO2

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 5/20 0.39
LMNA P02545 3/20 0.39
HTT P42858 2/20 0.39
BLM P54132 1/20 0.39
ITGB2 P05107 1/20 0.37
ICAM1 P05362 1/20 0.37
ITGAL P20701 1/20 0.37
NPC1 O15118 6/20 0.34
RAB9A P51151 6/20 0.34
GAA P10253 3/20 0.34
MEN1 O00255 2/20 0.34
KMT2A Q03164 2/20 0.34
MBOAT4 Q96T53 1/20 0.34
SMN1; SMN2 Q16637 6/20 0.33
CRHBP P24387 2/20 0.33
CRHR2 Q13324 2/20 0.33
MAOB P27338 1/20 0.33
ALDH1A1 P00352 3/20 0.31
TP53 P04637 1/20 0.31
KDM4E B2RXH2 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14910677 0.83 ABCG2 (0.37) MAPTLMNANPC1RAB9AGAA
SCHEMBL31003337 0.83 ABCG2 (0.37) MAPTLMNANPC1RAB9AGAA
SCHEMBL19844887 0.74 ITGB2 (0.37) MAPTLMNAHTTBLMITGB2
SCHEMBL2437286 0.74 MBOAT4 (0.40) MAPTLMNAHTTITGB2ICAM1
SCHEMBL19837330 0.74 ITGB2 (0.37) MAPTLMNAHTTBLMITGB2
SCHEMBL24156942 0.74 ITGB2 (0.37) MAPTLMNAHTTBLMITGB2
SCHEMBL2295626 0.74 MBOAT4 (0.40) MAPTLMNAHTTITGB2ICAM1
SCHEMBL31168492 0.74 MBOAT4 (0.40) MAPTLMNAHTTITGB2ICAM1
SCHEMBL2799966 0.74 MBOAT4 (0.43) MAPTLMNAHTTBLMITGB2
SCHEMBL23554439 0.74 CYP3A4 (0.36) MAPTITGB2ICAM1ITGALNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240043435-A1 TYK-2 INHIBITOR BEONE MEDICINES I GMBH (CH) 2024-02-08 US disclosed
EP-4168398-A1 TYK-2 INHIBITOR BeiGene, Ltd. (KY) 2023-04-26 EP disclosed
US-20140243302-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS MERCK SHARP & DOHME CORPORATION (US) 2014-08-28 US disclosed
EP-2723737-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS Kyorin Pharmaceutical Co., Ltd. (JP) 2014-04-30 EP disclosed
WO-2013003383-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS KYORIN PHARMACEUTICAL CO., LTD. (JP) 2013-01-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140243302-A1 BRIDGED BICYCLIC COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS PAICS, SBDS, SORD MAPT 2221/4885LMNA 2982/4885HTT 4742/4885
US-20240043435-A1 TYK-2 INHIBITOR TYK2, IRAK2, PTK2B MAPT 749/4885LMNA 3012/4885HTT 1701/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.